Patents Examined by Venkataraman Balasubramanian
  • Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
    Patent number: 10519121
    Abstract: Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 31, 2019
    Assignee: Apicore US LLC
    Inventors: Ravishanker Kovi, Jayaraman Rao Kannapan, Ananda Babu Thirunavakarasu, Veerabhadra Rao Bobbili, Gaurav Yadav
  • EGFR inhibitor compounds
    Patent number: 10513509
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 24, 2019
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • Pyrimidopyrrole compounds, method for preparing the same, pharmaceutical compositions comprising the same and uses thereof
    Patent number: 10508118
    Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 17, 2019
    Assignee: Xiamen University
    Inventors: Xianming Deng, Zhongji Zhuang, Zhou Deng, Xiaoxing Huang, Yan Liu, Ting Zhang, Wei Huang, Qingyan Xu, Zhiyu Hu
  • Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
    Patent number: 10494373
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 3, 2019
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Xile Liu, Linxia Xiao, Chao Ding, Fei Wang, Jian Li
  • Synthesis of copanlisib and its dihydrochloride salt
    Patent number: 10494372
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
  • Regioselective one-step process for synthesizing 2-hydroxyquinoxaline
    Patent number: 10487062
    Abstract: A regioselective one-step process for the synthesis of 2-hydroxyquinoxaline of Formula (1) or tautomers thereof: comprising reacting 1,2-phenylenediamine of Formula (2): with an excess amount of glyoxylic acid, glyoxylic acid monohydrate, or a 2,2-dialkoxyacetic acid of Formula (3): at a low temperature; wherein R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: November 26, 2019
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Shao-Zheng Peng, Yuan-Ting Cho, Pao-Chiung Hong
  • Compounds
    Patent number: 10479792
    Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: November 19, 2019
    Assignees: GiaxoSmithKline Intellectual Property Development Limited, University of Dundee
    Inventors: Stephen Brand, Peter George Dodd, Eun Jung Ko, Maria Marco Martin, Timothy James Miles, Lars Henrik Sandberg, Michael George Thomas, Stephen Thompson
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 10472367
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 12, 2019
    Assignees: INCYTE INCORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Compounds and compositions for inhibition of FASN
    Patent number: 10472342
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 12, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10457655
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 29, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Therapeutic compounds and methods of use thereof
    Patent number: 10457654
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 29, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Compounds and compositions for inhibition of FASN
    Patent number: 10450286
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: October 22, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
    Patent number: 10442789
    Abstract: Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: October 15, 2019
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Wenjin Yang, Qun Yin
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Azepine derivatives as 5-HTreceptor modulators
    Patent number: 10435408
    Abstract: Azepine derivatives acting on 5-HT7 receptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HT7 receptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HT7 receptors antagonistic activity is required.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: October 8, 2019
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyunah Choo, Youngjae Kim, Jihye Seong, Ghil Soo Nam, Yong Seo Cho
  • Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
    Patent number: 10435418
    Abstract: A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an ?-effect amine in aqueous solution at a temperature between about ?5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a boron compound having a boron atom bonded to a sp2 hybridized carbon conjugated with a cis-carbonyl, the boron having at least one labile substituent, with an ?-effect amine, in a solvent for a time sufficient to form an adduct, which may proceed to further products.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 8, 2019
    Assignee: The Research Foundation for the State University o
    Inventors: Susan Bane Tuttle, Ozlem Dilek, Kamalika Mukherjee
  • Cyclic compound and organic light-emitting element comprising same
    Patent number: 10431748
    Abstract: The present specification relates to a cyclic compound and an organic light emitting device comprising the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 1, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Dong Uk Heo, Dong Hoon Lee, Jungoh Huh, Boonjae Jang, Minyoung Kang, Miyeon Han
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 10421744
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: September 24, 2019
    Assignee: PFIZER INC.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Quinoxaline derivatives useful as FGFR kinase modulators
    Patent number: 10421747
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 24, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Wim Vermeulen, Steven Anna Hostyn, Filip Albert Celine Cuyckens, Russell Mark Jones, Diego Fernando Domenico Broggini
  • Inhibitor of endocannabinoid cellular reuptake
    Patent number: 10414721
    Abstract: Provided is a highly potent and selective endocannabioid cellular reuptake inhibitor represented by formula (I): or a pharmaceutically acceptable solvate or co-crystal thereof as well as to a formulation comprising this inhibitor, and to methods of treatment in which this inhibitor is used.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF BERN
    Inventors: Andrea Chicca, Jurg Gertsch